Zobrazeno 1 - 10
of 29
pro vyhledávání: '"David S. Ziegler"'
Autor:
Brittany C. McGill, Claire E. Wakefield, Kate Hetherington, Lachlan J. Munro, Meera Warby, Loretta Lau, Vanessa Tyrrell, David S. Ziegler, Tracey A. O’Brien, Glenn M. Marshall, David Malkin, Jordan R. Hansford, Katherine M. Tucker, Janine Vetsch
Publikováno v:
Journal of Personalized Medicine, Vol 10, Iss 1, p 9 (2020)
Precision medicine is changing cancer care and placing new demands on oncology professionals. Precision medicine trials for high-risk childhood cancer exemplify these complexities. We assessed clinicians’ (n = 39) and scientists’ (n = 15) experie
Externí odkaz:
https://doaj.org/article/8db62332cf95418bbfa148f62d31db0b
Autor:
Johannes H. Schulte, C. Michel Zwaan, David S. Ziegler, Michela Casanova, Matthias Fischer, Mario Stegert, Beate Wulff, Constantino Sábado, Meredith S. Irwin, Luojun Wang, Birgit Geoerger, Fabrice Branle, Felipe K. Hurtado, Lynley V. Marshall, Lucas Moreno
Publikováno v:
The Lancet Oncology, 22(12), 1764-1776. Lancet Publishing Group
Background: Several paediatric malignancies, including anaplastic large cell lymphoma (ALCL), inflammatory myofibroblastic tumour (IMT), neuroblastoma, and rhabdomyosarcoma, harbour activation of anaplastic lymphoma kinase (ALK) through different mec
Autor:
Michelle Haber, Rachael L. Terry, Joe Zhu, Paul J Neeson, Phillip K. Darcy, Deborah Meyran, David S. Ziegler, Paul G Ekert, Joseph A. Trapani
Publikováno v:
Annals of Oncology. 32:1366-1380
Chimeric antigen receptor (CAR)-T-cell therapy is a promising approach for the treatment of childhood cancers, particularly high-risk tumors that fail to respond to standard therapies. CAR-T cells have been highly successful in treating some types of
FOXR2 is an epigenetically regulated pan-cancer oncogene that activates ETS transcriptional circuits
Autor:
Jessica W. Tsai, Paloma Cejas, Dayle K. Wang, Smruti Patel, David W. Wu, Phonepasong Arounleut, Xin Wei, Ningxuan Zhou, Sudeepa Syamala, Frank P.B. Dubois, Alexander Crane, Kristine Pelton, Jayne Vogelzang, Cecilia Sousa, Audrey Baguette, Xiaolong Chen, Alexandra L. Condurat, Sarah E. Dixon-Clarke, Kevin N. Zhou, Sophie D. Lu, Elizabeth M. Gonzalez, Madison S. Chacon, Jeromy J. Digiacomo, Rushil Kumbhani, Dana Novikov, J'Ya Hunter, Maria Tsoli, David S. Ziegler, Uta Dirksen, Natalie Jager, Gnana Prakash Balasubramanian, Christof M. Kramm, Michaela Nathrath, Stefan Bielack, Suzanne J. Baker, Jinghui Zhang, James M. McFarland, Gad Getz, François Aguet, Nada Jabado, Olaf Witt, Stefan M. Pfister, Keith L. Ligon, Volker Hovestadt, Claudia L. Kleinman, Henry Long, David T.W. Jones, Pratiti Bandopadhayay, Timothy N. Phoenix
Publikováno v:
Cancer Res
Forkhead box R2 (FOXR2) is a forkhead transcription factor located on the X chromosome whose expression is normally restricted to the testis. In this study, we performed a pan-cancer analysis of FOXR2 activation across more than 10,000 adult and pedi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b04fde1eafeb27aba2cd478be2c63a8
https://europepmc.org/articles/PMC9437574/
https://europepmc.org/articles/PMC9437574/
Autor:
Jinhan Xie, Paulette Barahona, Michelle Haber, Emily Mould, Andrew J. Gifford, Loretta Lau, Amit Kumar, Timothy W. Failes, Marie Wong-Erasmus, Dylan Grebert-Wade, Greg M. Arndt, M. Emmy M. Dolman, Dong-Anh Khuong-Quang, Chelsea Mayoh, Kanika Bhatia, Shu-Oi Chow, Alvin Kamili, Roxanne Cadiz, Richard B. Lock, Maria Tsoli, Vanessa Tyrrell, David S. Ziegler, Glenn M. Marshall, Penny Athanasatos
Publikováno v:
Cancer Cytopathology. 129:805-818
Background The development of high-throughput drug screening (HTS) using primary cultures provides a promising, clinically translatable approach to tailoring treatment strategies for patients with cancer. However, this has been challenging for solid
Autor:
Cynthia Hawkins, Daniel A. Morgenstern, Victoria J. Forster, Scott Lindhorst, Sumedha Sudhaman, Uri Tabori, An Van Damme, Eric Bouffet, Alexander Lossos, Ben George, Annika Bronsema, Anita Villani, Michael Osborn, Annie Huang, Yosef E. Maruvka, Melyssa Aronson, Patrick Tomboc, Michal Yalon-Oren, David S. Ziegler, Reid Hayes, Carol Durno, Vanessa Bianchi, Melissa Galati, Nuno Miguel Nunes, Magimairajan Issai Vanan, Vanja Cabric, Gregory Thomas, Nicholas Light, Scott Davidson, Matthew Zatzman, Michael D. Taylor, A. Sorana Morrissy, Martin Komosa, Melissa Edwards, Gary Mason, Jiil Chung, Adam Shlien, Gad Getz, Shriya Deshmukh, Alyssa Reddy, Karl P. Hodel, Zachary F. Pursell, Robert Siddaway, Maura Massimino, Enrico Opocher, Ledia Brunga, David Malkin, Ben Ho, Jacalyn Kelly, Daniel C. Bowers, Nathaniel D. Anderson, Valerie Larouche, Thomas A. Kunkel, Nicholas J. Haradhvala, Kristina A. Cole
Publikováno v:
Cancer Discov
Cancer discovery, Vol. 11, no. 5, p. 1176-1191 (2021)
Cancer discovery, Vol. 11, no. 5, p. 1176-1191 (2021)
Although replication repair deficiency, either by mismatch repair deficiency (MMRD) and/or loss of DNA polymerase proofreading, can cause hypermutation in cancer, microsatellite instability (MSI) is considered a hallmark of MMRD alone. By genome-wide
In vitro and in vivo drug screens of tumor cells identify novel therapies for high‐risk child cancer
Autor:
Loretta M S Lau, Chelsea Mayoh, Jinhan Xie, Paulette Barahona, Karen L MacKenzie, Marie Wong, Alvin Kamili, Maria Tsoli, Tim W Failes, Amit Kumar, Emily V A Mould, Andrew Gifford, Shu‐Oi Chow, Mark Pinese, Jamie I Fletcher, Greg M Arndt, Dong‐Anh Khuong‐Quang, Carol Wadham, Daniel Batey, Georgina Eden, Peter Trebilcock, Swapna Joshi, Stephanie Alfred, Anjana Gopalakrishnan, Aaminah Khan, Dylan Grebert Wade, Patrick A Strong, Elodie Manouvrier, Lisa T Morgan, Miriam Span, Jin Yi Lim, Roxanne Cadiz, Caitlin Ung, David M Thomas, Katherine M Tucker, Meera Warby, Geoffrey B McCowage, Luciano Dalla‐Pozza, Jennifer A Byrne, Federica Saletta, Andrew Fellowes, Stephen B Fox, Murray D Norris, Vanessa Tyrrell, Toby N Trahair, Richard B Lock, Mark J Cowley, Paul G Ekert, Michelle Haber, David S Ziegler, Glenn M Marshall
Publikováno v:
EMBO Molecular Medicine. 14
Biomarkers which better match anticancer drugs with cancer driver genes hold the promise of improved clinical responses and cure rates. We developed a precision medicine platform of rapid high-throughput drug screening (HTS) and patient-derived xenog
Autor:
Josée Brossard, Kathleen Felton, Jemma Say, Adam Fleming, Valerie Larouche, Ronald Grant, Katherine A Blood, Uri Tabori, Melissa Tachdjian, Chantel Cacciotti, Rawan Hammad, Noelle Cullinan, Catherine Goudie, Vijay Ramaswamy, Lucie Lafay-Cousin, Kalene van Engelen, Kim E. Nichols, Ledia Brunga, Linlea Armstrong, Kimberly Caswell, Stephanie Vairy, Jonathan D. Wasserman, Mary Egan Clark, Conrad V. Fernandez, Katherine M. Tucker, Nandini Dendukuri, James A. Whitlock, Ian Schiller, David Malkin, Gino Somers, Annie-Kim Toupin, Nada Jabado, M. Stephen Meyn, Nicolas Waespe, Sonia Cellot, Daniel Sinnett, Paul Gibson, My Linh Thibodeau, Donna L. Johnston, William D. Foulkes, Rebecca J. Deyell, Angela Punnett, David S. Ziegler, Irene Lara-Corrales, Junne Kamihara, Sarah R. Kane, Meghan Pike, Natalie Mathews, Catherine Clinton, Renee Perrier, Lynn W. Harrison, Meredith S. Irwin, Noemi Fuentes-Bolanos, Orli Michaeli, Meera Warby, Adam Shlien, Leora Witkowski, Anita Villani, Hallie Coltin, Paul C. Nathan, Lara Reichman
Publikováno v:
JAMA Oncol
Importance Prompt recognition of a child with a cancer predisposition syndrome (CPS) has implications for cancer management, surveillance, genetic counseling, and cascade testing of relatives. Diagnosis of CPS requires practitioner expertise, access
Autor:
Rogier Versteeg, Gian Paolo Tonini, Gudrun Schleiermacher, Amanda J. Russell, Angelika Eggert, Murray D. Norris, Jaydutt Bhalshankar, Michael D. Hogarty, Tom Van Maerken, Glenn M. Marshall, Mark J. Cowley, Kwun M. Fong, Lesley J. Ashton, John M. Maris, Sharon J. Diskin, Michelle Haber, Jayne Murray, Michelle J. Henderson, Stefania Purgato, Raymond L. Stallings, Jan Koster, Paolo Pigini, Ali Rihani, Zalman Vaksman, Jo Vandesompele, Wendy B. London, Rosa Noguera, Emanuele Valli, Laura D. Gamble, Franki Speleman, Federico M. Giorgi, Giovanni Perini, Giorgio Milazzo, Simone Di Giacomo, David S. Ziegler
Publikováno v:
Cancers, 13(8):1807. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Cancers, Vol 13, Iss 1807, p 1807 (2021)
Volume 13
Issue 8
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
CANCERS
Cancers
Cancers, Vol 13, Iss 1807, p 1807 (2021)
Volume 13
Issue 8
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
CANCERS
Simple Summary Neuroblastoma is a devasting childhood cancer in which multiple copies (amplification) of the cancer-causing gene MYCN strongly predict poor outcome. Neuroblastomas are reliant on high levels of cellular components called polyamines fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4917908fda62bba8644d6ef88dfa1048
https://pure.amc.nl/en/publications/a-g316a-polymorphism-in-the-ornithine-decarboxylase-gene-promoter-modulates-mycndriven-childhood-neuroblastoma(a76771d0-831a-4b04-9af8-31acd810ac62).html
https://pure.amc.nl/en/publications/a-g316a-polymorphism-in-the-ornithine-decarboxylase-gene-promoter-modulates-mycndriven-childhood-neuroblastoma(a76771d0-831a-4b04-9af8-31acd810ac62).html
Autor:
Robert A. Battisti, Tracey A. O'Brien, Eden G. Robertson, Richard Mitchell, Claire E. Wakefield, David S. Ziegler, Richard J. Cohn, Mark Donoghoe, Joanna E. Fardell
Publikováno v:
Psycho-Oncology. 28:1520-1529
OBJECTIVE Families of a child with cancer can find the decision to enrol in a clinical trial challenging and often misunderstand key concepts that underpin trials. We pilot tested "Delta," an online and booklet decision aid for parents with a child w